View Article

Abstract

Etoposide is a semisynthetic derivative of podophyllotoxin widely used as a chemotherapeutic agent in the treatment of various malignancies such as lung cancer, testicular cancer, lymphomas, and leukemias. Despite its proven clinical efficacy, its therapeutic use is limited due to poor aqueous solubility, variable oral bioavailability, systemic toxicity, and the development of multidrug resistance. Conventional dosage forms of etoposide often fail to achieve optimal therapeutic outcomes and are associated with severe side effects. Liposomal drug delivery systems have emerged as a promising approach to overcome these challenges by improving solubility, protecting the drug from degradation, prolonging circulation half-life, enhancing tumor accumulation through the enhanced permeability and retention effect, and reducing systemic adverse effects.This review article provides a detailed discussion on the formulation and evaluation of liposomal drug delivery systems for etoposide. It highlights the fundamental challenges of conventional etoposide therapy, the design and preparation of liposomes, and the formulation strategies employed to optimize etoposide-loaded liposomes. In addition, key evaluation parameters such as particle size, zeta potential, drug entrapment efficiency, stability, and release kinetics are discussed in detail. Preclinical and clinical findings are summarized to illustrate the therapeutic advantages of liposomal etoposide. Furthermore, the article explores recent advancements in targeted and stimuli-responsive liposomes, challenges in large-scale development, and future directions in cancer nanomedicine. By integrating current scientific insights with critical evaluation, this review aims to provide a comprehensive understanding of the role of liposomal delivery systems in enhancing the therapeutic potential of etoposide and paving the way for improved patient outcomes in oncology.

Keywords

Etoposide, liposomes, anticancer therapy, drug delivery systems, nanomedicine, formulation, evaluation, pharmacokinetics, chemotherapy

Introduction

Cancer is one of the leading causes of mortality and morbidity worldwide, representing a major global health challenge [1]. The management of cancer often involves chemotherapy, radiotherapy, surgery, or a combination of these modalities. Among these, chemotherapy plays a critical role, especially in metastatic or systemic malignancies. However, conventional chemotherapy is associated with several limitations, including poor selectivity, systemic toxicity, and the emergence of drug resistance [2]. These challenges significantly compromise therapeutic efficacy and patient quality of life.

Reference

  1. Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. CA: A Cancer Journal for Clinicians, 70(1), 7–30. https://doi.org/10.3322/caac.21590
  2. Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013). Cancer drug resistance: An evolving paradigm. Nature Reviews Cancer, 13(10), 714–726. https://doi.org/10.1038/nrc3599
  3. Pommier, Y. (2006). Topoisomerase II inhibitors: Etoposide and beyond. Nature Reviews Cancer, 6(10), 789–802. https://doi.org/10.1038/nrc1977
  4. Hande, K. R. (1998). Etoposide: Four decades of development of a topoisomerase II inhibitor. European Journal of Cancer, 34(10), 1514–1521. https://doi.org/10.1016/S0959-8049(98)00197-2
  5. Kummar, S., Chen, A. P., Wright, J., et al. (2007). Phase I study of oral etoposide in patients with advanced solid tumors. Clinical Cancer Research, 13(11), 3377–3383. https://doi.org/10.1158/1078-0432.CCR-06-2708
  6. Gelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A. (2001). Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. European Journal of Cancer, 37(13), 1590–1598. https://doi.org/10.1016/S0959-8049(01)00142-2
  7. McGuire, W. P., Hoskins, W. J., Brady, M. F., et al. (1996). Cyclophosphamide and etoposide in combination therapy. Journal of Clinical Oncology, 14(5), 1646–1655. https://doi.org/10.1200/JCO.1996.14.5.1646
  8. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36–48. https://doi.org/10.1016/j.addr.2012.09.037
  9. Bozzuto, G., & Molinari, A. (2015). Liposomes as nanomedical devices. International Journal of Nanomedicine, 10, 975–999. https://doi.org/10.2147/IJN.S68861
  10. Sercombe, L., Veerati, T., Moheimani, F., et al. (2015). Advances and challenges of liposome assisted drug delivery. Frontiers in Pharmacology, 6, 286. https://doi.org/10.3389/fphar.2015.00286
  11. Barenholz, Y. (2012). Doxil® — The first FDA-approved nano-drug: Lessons learned. Journal of Controlled Release, 160(2), 117–134. https://doi.org/10.1016/j.jconrel.2012.03.020
  12. Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 4(2), 145–160. https://doi.org/10.1038/nrd1632
  13. Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. Journal of Controlled Release, 65(1–2), 271–284. https://doi.org/10.1016/S0168-3659(99)00248-5
  14. Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003). Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies. Clinical Pharmacokinetics, 42(5), 419–436. https://doi.org/10.2165/00003088-200342050-00002
  15. Slater, E. P., & Folkman, J. (1984). Podophyllotoxin and derivatives as anticancer agents. Cancer Treatment Reviews, 11(3), 165–182. https://doi.org/10.1016/S0305-7372(84)80005-5
  16. Kinghorn, A. D., & Pan, L. (2012). Etoposide: Chemistry and pharmacology. Natural Product Reports, 29(8), 967–988. https://doi.org/10.1039/c2np20035f
  17. Hande, K. R. (1998). Etoposide: Four decades of development of a topoisomerase II inhibitor. European Journal of Cancer, 34(10), 1514–1521. https://doi.org/10.1016/S0959-8049(98)00197-2
  18. Pommier, Y., Leo, E., Zhang, H., & Marchand, C. (2010). DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chemistry & Biology, 17(5), 421–433. https://doi.org/10.1016/j.chembiol.2010.04.012
  19. Gewirtz, D. A. (1999). A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics. Biochemical Pharmacology, 57(7), 727–741. https://doi.org/10.1016/S0006-2952(98)00399-1
  20. Gelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A. (2001). Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. European Journal of Cancer, 37(13), 1590–1598. https://doi.org/10.1016/S0959-8049(01)00142-2
  21. Kummar, S., Chen, A. P., Wright, J., et al. (2007). Phase I study of oral etoposide in patients with advanced solid tumors. Clinical Cancer Research, 13(11), 3377–3383. https://doi.org/10.1158/1078-0432.CCR-06-2708
  22. Sparreboom, A., & Verweij, J. (1999). Pharmacokinetics of etoposide and determinants of oral bioavailability. Clinical Pharmacokinetics, 36(6), 447–460. https://doi.org/10.2165/00003088-199936060-00002
  23. Hande, K. R. (1998). Etoposide: Four decades of development of a topoisomerase II inhibitor. European Journal of Cancer, 34(10), 1514–1521. https://doi.org/10.1016/S0959-8049(98)00197-2
  24. Gelderblom, H., et al. (2001). European Journal of Cancer, 37(13), 1590–1598.
  25. McGuire, W. P., et al. (1996). Journal of Clinical Oncology, 14(5), 1646–1655.
  26. Holohan, C., et al. (2013). Nature Reviews Cancer, 13(10), 714–726.
  27. Pommier, Y. (2006). Nature Reviews Cancer, 6(10), 789–802.
  28. Allen, T. M., & Cullis, P. R. (2013). Advanced Drug Delivery Reviews, 65(1), 36–48.
  29. Bozzuto, G., & Molinari, A. (2015). International Journal of Nanomedicine, 10, 975–999.
  30. Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965). Diffusion of univalent ions across the lamellae of swollen phospholipids. Journal of Molecular Biology, 13(1), 238–252. https://doi.org/10.1016/S0022-2836(65)80199-0
  31. Gregoriadis, G. (1995). Engineering liposomes for drug delivery: Progress and problems. Trends in Biotechnology, 13(12), 527–537. https://doi.org/10.1016/S0167-7799(00)88934-4
  32. Allen, T. M. (1994). Liposomal drug formulations: Rationale and prospects for cancer therapy. Drugs, 47(1), 25–36. https://doi.org/10.2165/00003495-199447010-00003
  33. Gabizon, A., et al. (2003). Clinical Pharmacokinetics, 42(5), 419–436.
  34. Lasic, D. D., & Papahadjopoulos, D. (1998). Medical Applications of Liposomes. Elsevier.
  35. Yatvin, M. B., Weinstein, J. N., Dennis, W. H., & Blumenthal, R. (1978). Design of liposomes for enhanced local release of drugs by hyperthermia. Science, 202(4374), 1290–1293. https://doi.org/10.1126/science.688834
  36. Bangham, A. D., et al. (1965). Journal of Molecular Biology, 13(1), 238–252.
  37. Torchilin, V. P. (2005). Nature Reviews Drug Discovery, 4(2), 145–160.
  38. Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. Journal of Controlled Release, 65(1–2), 271–284. https://doi.org/10.1016/S0168-3659(99)00248-5
  39. Barenholz, Y. (2012). Doxil® — The first FDA-approved nano-drug: Lessons learned. Journal of Controlled Release, 160(2), 117–134. https://doi.org/10.1016/j.jconrel.2012.03.020
  40. Harde, H., Das, M., & Jain, S. (2011). Liposomes: Preparation, characterization and applications. International Journal of Pharmaceutical Sciences Review and Research, 7(2), 1–8.
  41. Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965). Diffusion of univalent ions across the lamellae of swollen phospholipids. Journal of Molecular Biology, 13(1), 238–252. https://doi.org/10.1016/S0022-2836(65)80199-0
  42. Szoka, F., & Papahadjopoulos, D. (1980). Comparative properties and methods of preparation of lipid vesicles (liposomes). Annual Review of Biophysics and Bioengineering, 9, 467–508. https://doi.org/10.1146/annurev.bb.09.060180.002343
  43. Jahn, A., Vreeland, W. N., Gaitan, M., & Locascio, L. E. (2004). Controlled vesicle self-assembly in microfluidic channels with hydrodynamic focusing. Journal of the American Chemical Society, 126(9), 2674–2675. https://doi.org/10.1021/ja039725u
  44. Cegelski, L., & Vreeland, W. N. (2011). Liposome microfluidic technologies for drug delivery. Lab on a Chip, 11(22), 3826–3836. https://doi.org/10.1039/c1lc20543a
  45. New, R. R. C. (1990). Liposomes: A Practical Approach. Oxford University Press.
  46. Mozafari, M. R. (2005). Liposomes: An overview of manufacturing techniques. Cellular and Molecular Biology Letters, 10(4), 711–719.
  47. Immordino, M. L., Dosio, F., & Cattel, L. (2006). Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. International Journal of Nanomedicine, 1(3), 297–315. https://doi.org/10.2147/nano.2006.1.3.297
  48. Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., et al. (2013). Liposome: Classification, preparation, and applications. Nanoscale Research Letters, 8, 102. https://doi.org/10.1186/1556-276X-8-102
  49. Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 4(2), 145–160. https://doi.org/10.1038/nrd1632
  50. Patil, Y., & Jadhav, S. (2014). Liposomal drug delivery: A comprehensive review. International Journal of Pharmaceutical Research & Development, 6(11), 1–10.
  51. Gupta, A., & Kumar, P. (2010). Liposome drug delivery system: A review. Journal of Advanced Pharmaceutical Technology & Research, 1(4), 374–382. https://doi.org/10.4103/2231-4040.90790
  52. Shaji, J., & Patole, V. (2008). Protein and peptide drug delivery: Oral approaches. Indian Journal of Pharmaceutical Sciences, 70(3), 269–277. https://doi.org/10.4103/0250-474X.43017
  53. Mozafari, M. R., Johnson, C., Hatziantoniou, S., & Demetzos, C. (2008). Nanoliposomes and their applications in food and pharmaceutical sectors. Journal of Liposome Research, 18(3), 309–327. https://doi.org/10.1080/08982100802335964
  54. Deshpande, P., Bisht, S., & Maitra, A. (2009). Evaluation of liposomal anticancer drug formulations. Current Opinion in Investigational Drugs, 10(12), 1334–1341.
  55. Wang, Y., & Yu, H. (2014). Characterization of liposomal drug delivery systems: Particle size and PDI. Journal of Pharmaceutical Analysis, 4(5), 295–302. https://doi.org/10.1016/j.jpha.2014.06.001
  56. Jain, S., & Jain, R. (2015). Zeta potential and stability evaluation of liposomes: A review. International Journal of Pharmaceutical Sciences and Research, 6(3), 882–890. https://doi.org/10.13040/IJPSR.0975-8232.6(3).882-90
  57. Akbarzadeh, A., et al. (2013). Liposome: Classification, preparation, and applications. Nanoscale Research Letters, 8, 102. https://doi.org/10.1186/1556-276X-8-102
  58. ozafari, M. R. (2005). Liposomes: An overview of manufacturing techniques. Cellular and Molecular Biology Letters, 10(4), 711–719.
  59. Kulkarni, A., & Feng, S. S. (2013). In vitro drug release from liposomes: Methods and kinetics. International Journal of Pharmaceutics, 458(1), 116–123. https://doi.org/10.1016/j.ijpharm.2013.09.015
  60. Immordino, M. L., et al. (2006). Stealth liposomes: Review of the basic science, rationale, and clinical applications. International Journal of Nanomedicine, 1(3), 297–315. https://doi.org/10.2147/nano.2006.1.3.297
  61. Deshpande, P., et al. (2009). Evaluation of liposomal anticancer drug formulations. Current Opinion in Investigational Drugs, 10(12), 1334–1341.
  62. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36–48. https://doi.org/10.1016/j.addr.2012.09.037
  63. Bozzuto, G., & Molinari, A. (2015). Liposomes as nanomedical devices. International Journal of Nanomedicine, 10, 975–999. https://doi.org/10.2147/IJN.S68861
  64. Immordino, M. L., Dosio, F., & Cattel, L. (2006). Stealth liposomes: Review of the basic science, rationale, and clinical applications. International Journal of Nanomedicine, 1(3), 297–315. https://doi.org/10.2147/nano.2006.1.3.297
  65. Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003). Pharmacokinetics of pegylated liposomal doxorubicin: Review of animal and human studies. Clinical Pharmacokinetics, 42(5), 419–436. https://doi.org/10.2165/00003088-200342050-00002
  66. Allen, T. M., Hansen, C. B., de Menezes, D., et al. (1991). Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochimica et Biophysica Acta (BBA) – Biomembranes, 1066(1), 29–36. https://doi.org/10.1016/0005-2736(91)90143-X
  67. Maeda, H. (2001). The enhanced permeability and retention (EPR) effect in tumor vasculature: The key for tumor-selective drug targeting. Advances in Enzyme Regulation, 41, 189–207. https://doi.org/10.1016/S0065-2571(00)00013-3
  68. Immordino, M. L., et al. (2006). Stealth liposomes: Review of the basic science, rationale, and clinical applications. International Journal of Nanomedicine, 1(3), 297–315. https://doi.org/10.2147/nano.2006.1.3.297
  69. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36–48. https://doi.org/10.1016/j.addr.2012.09.037
  70. Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 4(2), 145–160. https://doi.org/10.1038/nrd1632
  71. Kummar, S., Chen, A. P., Wright, J., et al. (2007). Phase I study of oral etoposide in patients with advanced solid tumors. Clinical Cancer Research, 13(11), 3377–3383. https://doi.org/10.1158/1078-0432.CCR-06-2708
  72. Hande, K. R. (1998). Etoposide: Four decades of development of a topoisomerase II inhibitor. European Journal of Cancer, 34(10), 1514–1521. https://doi.org/10.1016/S0959-8049(98)00197-2
  73. Gabizon, A., et al. (2003). Pharmacokinetics of pegylated liposomal doxorubicin: Review of animal and human studies. Clinical Pharmacokinetics, 42(5), 419–436. https://doi.org/10.2165/00003088-200342050-00002
  74. Deshpande, P., Bisht, S., & Maitra, A. (2009). Evaluation of liposomal anticancer drug formulations. Current Opinion in Investigational Drugs, 10(12), 1334–1341.
  75. Allen, T. M., Hansen, C. B., de Menezes, D., et al. (1991). Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochimica et Biophysica Acta (BBA) – Biomembranes, 1066(1), 29–36. https://doi.org/10.1016/0005-2736(91)90143-X
  76. Mozafari, M. R., Johnson, C., Hatziantoniou, S., & Demetzos, C. (2008). Nanoliposomes and their applications in food and pharmaceutical sectors. Journal of Liposome Research, 18(3), 309–327. https://doi.org/10.1080/08982100802335964
  77. Gelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A. (2001). Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. European Journal of Cancer, 37(13), 1590–1598. https://doi.org/10.1016/S0959-8049(01)00142-2
  78. Sparreboom, A., & Verweij, J. (1999). Pharmacokinetics of etoposide and determinants of oral bioavailability. Clinical Pharmacokinetics, 36(6), 447–460. https://doi.org/10.2165/00003088-199936060-00002
  79. McGuire, W. P., Hoskins, W. J., Brady, M. F., et al. (1996). Cyclophosphamide and etoposide in combination therapy. Journal of Clinical Oncology, 14(5), 1646–1655. https://doi.org/10.1200/JCO.1996.14.5.1646
  80. Harde, H., Das, M., & Jain, S. (2011). Liposomes: Preparation, characterization and applications. International Journal of Pharmaceutical Sciences Review and Research, 7(2), 1–8.
  81. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36–48. https://doi.org/10.1016/j.addr.2012.09.037
  82. Bozzuto, G., & Molinari, A. (2015). Liposomes as nanomedical devices. International Journal of Nanomedicine, 10, 975–999. https://doi.org/10.2147/IJN.S68861
  83. Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 4(2), 145–160. https://doi.org/10.1038/nrd1632
  84. Immordino, M. L., Dosio, F., & Cattel, L. (2006). Stealth liposomes: Review of the basic science, rationale, and clinical applications. International Journal of Nanomedicine, 1(3), 297–315. https://doi.org/10.2147/nano.2006.1.3.297
  85. Kulkarni, A., & Feng, S. S. (2013). In vitro drug release from liposomes: Methods and kinetics. International Journal of Pharmaceutics, 458(1), 116–123. https://doi.org/10.1016/j.ijpharm.2013.09.015
  86. Deshpande, P., et al. (2009). Evaluation of liposomal anticancer drug formulations. Current Opinion in Investigational Drugs, 10(12), 1334–1341.
  87. Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003). Pharmacokinetics of pegylated liposomal doxorubicin: Review of animal and human studies. Clinical Pharmacokinetics, 42(5), 419–436. https://doi.org/10.2165/00003088-200342050-00002
  88. Maeda, H. (2001). The enhanced permeability and retention (EPR) effect in tumor vasculature: The key for tumor-selective drug targeting. Advances in Enzyme Regulation, 41, 189–207. https://doi.org/10.1016/S0065-2571(00)00013-3
  89. Allen, T. M., Hansen, C. B., de Menezes, D., et al. (1991). Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochimica et Biophysica Acta (BBA) – Biomembranes, 1066(1), 29–36. https://doi.org/10.1016/0005-2736(91)90143-X
  90. Mozafari, M. R., Johnson, C., Hatziantoniou, S., & Demetzos, C. (2008). Nanoliposomes and their applications in food and pharmaceutical sectors. Journal of Liposome Research, 18(3), 309–327. https://doi.org/10.1080/08982100802335964
  91. Akbarzadeh, A., et al. (2013). Liposome: Classification, preparation, and applications. Nanoscale Research Letters, 8, 102. https://doi.org/10.1186/1556-276X-8-102
  92. Patil, Y., & Jadhav, S. (2014). Liposomal drug delivery: A comprehensive review. International Journal of Pharmaceutical Research & Development, 6(11), 1–10.
  93. Gupta, A., & Kumar, P. (2010). Liposome drug delivery system: A review. Journal of Advanced Pharmaceutical Technology & Research, 1(4), 374–382. https://doi.org/10.4103/2231-4040.90790
  94. Shaji, J., & Patole, V. (2008). Protein and peptide drug delivery: Oral approaches. Indian Journal of Pharmaceutical Sciences, 70(3), 269–277. https://doi.org/10.4103/0250-474X.43017
  95. Harde, H., Das, M., & Jain, S. (2011). Liposomes: Preparation, characterization and applications. International Journal of Pharmaceutical Sciences Review and Research, 7(2), 1–8.
  96. Kulkarni, A., & Feng, S. S. (2013). In vitro drug release from liposomes: Methods and kinetics. International Journal of Pharmaceutics, 458(1), 116–123. https://doi.org/10.1016/j.ijpharm.2013.09.015
  97. Immordino, M. L., et al. (2006). Stealth liposomes: Review of the basic science, rationale, and clinical applications. International Journal of Nanomedicine, 1(3), 297–315. https://doi.org/10.2147/nano.2006.1.3.297
  98. Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 4(2), 145–160. https://doi.org/10.1038/nrd1632
  99. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36–48. https://doi.org/10.1016/j.addr.2012.09.037
  100. Bozzuto, G., & Molinari, A. (2015). Liposomes as nanomedical devices. International Journal of Nanomedicine, 10, 975–999. https://doi.org/10.2147/IJN.S68861
  101. Gelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A. (2001). Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. European Journal of Cancer, 37(13), 1590–1598. https://doi.org/10.1016/S0959-8049(01)00142-2
  102. Sparreboom, A., & Verweij, J. (1999). Pharmacokinetics of etoposide and determinants of oral bioavailability. Clinical Pharmacokinetics, 36(6), 447–460. https://doi.org/10.2165/00003088-199936060-00002
  103. McGuire, W. P., Hoskins, W. J., Brady, M. F., et al. (1996). Cyclophosphamide and etoposide in combination therapy. Journal of Clinical Oncology, 14(5), 1646–1655. https://doi.org/10.1200/JCO.1996.14.5.1646
  104. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65(1), 36–48. https://doi.org/10.1016/j.addr.2012.09.037
  105. Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003). Pharmacokinetics of pegylated liposomal doxorubicin: Review of animal and human studies. Clinical Pharmacokinetics, 42(5), 419–436. https://doi.org/10.2165/00003088-200342050-00002
  106. Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 4(2), 145–160. https://doi.org/10.1038/nrd1632
  107. Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. Journal of Controlled Release, 65(1–2), 271–284. https://doi.org/10.1016/S0168-3659(99)00248-5
  108. Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013). Cancer drug resistance: An evolving paradigm. Nature Reviews Cancer, 13(10), 714–726. https://doi.org/10.1038/nrc3599
  109. Hande, K. R. (1998). Etoposide: Four decades of development of a topoisomerase II inhibitor. European Journal of Cancer, 34(10), 1514–1521. https://doi.org/10.1016/S0959-8049(98)00197-2
  110. Pommier, Y. (2006). Topoisomerase II inhibitors: Etoposide and beyond. Nature Reviews Cancer, 6(10), 789–802. https://doi.org/10.1038/nrc1977
  111. Kinghorn, A. D., & Pan, L. (2012). Etoposide: Chemistry and pharmacology. Natural Product Reports, 29(8), 967–988. https://doi.org/10.1039/c2np20035f
  112. Kummar, S., Chen, A. P., Wright, J., et al. (2007). Phase I study of oral etoposide in patients with advanced solid tumors. Clinical Cancer Research, 13(11), 3377–3383. https://doi.org/10.1158/1078-0432.CCR-06-2708
  113. Gelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A. (2001). Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. European Journal of Cancer, 37(13), 1590–1598. https://doi.org/10.1016/S0959-8049(01)00142-2
  114. Slater, E. P., & Folkman, J. (1984). Podophyllotoxin and derivatives as anticancer agents. Cancer Treatment Reviews, 11(3), 165–182. https://doi.org/10.1016/S0305-7372(84)80005-5
  115. Gewirtz, D. A. (1999). A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics. Biochemical Pharmacology, 57(7), 727–741. https://doi.org/10.1016/S0006-2952(98)00399-1
  116. Barenholz, Y. (2012). Doxil® — The first FDA-approved nano-drug: Lessons learned. Journal of Controlled Release, 160(2), 117–134. https://doi.org/10.1016/j.jconrel.2012.03.020.

Photo
Rushikesh Nirgude
Corresponding author

Matoshri College of Pharmacy, Eklahare, Nashik

Photo
Vedika Pagar
Co-author

Matoshri College of Pharmacy, Eklahare, Nashik

Photo
Ragini Kadvekar
Co-author

Matoshri College of Pharmacy, Eklahare, Nashik

Rushikesh Nirgude*, Vedika Pagar, Ragini Kadvekar, Formulation and Evaluation of Etoposide Liposomal Drug Delivery Systems, Int. J. Sci. R. Tech., 2025, 2 (10), 410-427. https://doi.org/10.5281/zenodo.17444421

More related articles
Formulation and Evaluation of Herbal Ointment from...
Anil Panchal, Abdul Kalam Abdul Jabbar Nadaf, Vishal Madankar, MD...
Design of Experiments in the Formulation and Optim...
Kartik Shinde, Dr. Nilesh Gorde, Swapnil Phalak, Prajval Birajdar...
Formulation and Evaluation of Dexlansoprazole-Load...
Aashwini Ghuge , Dr. Pravin Wakte, Dr. Sachin Bhusari , Renuka Dh...
View more
Galaxy Ride: Procedural Generation, AI-Driven Interaction, And Scalable Architec...
Ms .Dipanjali D. Shipne, Kshitij Ram Asole, Shivprasad Pradip Theng, Pratik Vijay Dhone , Sunil Ba...
Comprehensive Review of Polycystic Kidney Disease and Herbal Ingredients for its...
Poonam Yadav, Sushil Patil, Granthali Shape, ...
A Comprehensive Review on Herbal Sunscreen Lotions: Formulation Approaches, Eval...
Mrunali Patil, Krunal Sabale, Sahil Prajapati, Prathamesh Salunkhe, Shital Jadhav, Dr. Bhagyesh U Ja...
View more
Download PDF
Related Articles
Comprehensive Pharmacological Study of Cannabis Sativa Plant...
Akshay Wagh, Kunal Kothawade, Shivshankar Ambhore, Dr. Avinash Darekar , ...
Formulation and Development of Nanostructured Lipid Carrier for Glaucoma...
Sampada Potdar, Dr. A. H. Hosmani, Sharayu Gotpagar, Rutuja Kadam, Lovely Jain, Rutuja Sawakhande, R...
Formulation of Fast Dissolving Tablet Using Banana Peel Powder...
Pooja Rathore, Rahul Bisen, Prachi Rahangdale, Pulkit Prajapati, Pradhuuman Patel, Prince Kushwaha, ...
Formulation and Evaluation of Antiacne Topical Emulgel: A Comprehensive Review...
Nilesh Pawar, Yashpal More, Om Birari, Harshal Gosavi, ...
Formulation and Evaluation of Herbal Ointment from Neem and Turmeric Extract...
Anil Panchal, Abdul Kalam Abdul Jabbar Nadaf, Vishal Madankar, MD Tanvir Hamid Karajagikar, ...
More related articles
Formulation and Evaluation of Herbal Ointment from Neem and Turmeric Extract...
Anil Panchal, Abdul Kalam Abdul Jabbar Nadaf, Vishal Madankar, MD Tanvir Hamid Karajagikar, ...
Design of Experiments in the Formulation and Optimization of Sustained Release M...
Kartik Shinde, Dr. Nilesh Gorde, Swapnil Phalak, Prajval Birajdar, Vishal Bodke, ...
Formulation and Evaluation of Dexlansoprazole-Loaded Solid Lipid Nanoparticles f...
Aashwini Ghuge , Dr. Pravin Wakte, Dr. Sachin Bhusari , Renuka Dhakne, Dr. Preeti Sable , ...
View more
Formulation and Evaluation of Herbal Ointment from Neem and Turmeric Extract...
Anil Panchal, Abdul Kalam Abdul Jabbar Nadaf, Vishal Madankar, MD Tanvir Hamid Karajagikar, ...
Design of Experiments in the Formulation and Optimization of Sustained Release M...
Kartik Shinde, Dr. Nilesh Gorde, Swapnil Phalak, Prajval Birajdar, Vishal Bodke, ...
Formulation and Evaluation of Dexlansoprazole-Loaded Solid Lipid Nanoparticles f...
Aashwini Ghuge , Dr. Pravin Wakte, Dr. Sachin Bhusari , Renuka Dhakne, Dr. Preeti Sable , ...
View more

Copyright © 2025 IJSRT. All rights reserved